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Abstract 
Cancer-related fatigue (CRF) is a distressing symptom frequently experienced by 
patients with advanced cancer. While there have been some advances in the 
understanding of the management of fatigue associated with cancer treatment, CRF 
associated with advanced cancer remains a phenomenon that is not well-managed. 
The aetiologic factors associated with CRF, the impacts of CRF and the current 
management of CRF are discussed in this review article in relation to patients with 
advanced cancer. The paper concludes that while further research is required in the 
area, there are several potentially effective strategies currently available that can 
reduce the severity of CRF in patients with advanced cancer.  
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Introduction 
Fatigue is one of the most frequently experienced (1-3) and distressing symptoms (4, 
5) reported by patients with advanced cancer. The prevalence and impact of fatigue 
in this population, however, is not often acknowledged or understood by health 
professionals (6, 7). The likely reasons for this are that health professionals tend to 
focus more on pain or other more obvious symptoms (8); health professionals’ and 
patients’ lack of awareness of effective treatments for this symptom (7). Over the 
past few decades, however, for patients at all stages of the cancer trajectory, there 
has been a substantial body of research that has enhanced our understanding of the 
pathophysiology of fatigue, patients’ experiences of this symptom, and potentially 
effective interventions for patients who report cancer-related fatigue (CRF). It should 
be noted, however, that most of this research does not pertain to patients with 
advanced cancer (1, 2); it has focused to date largely on patients undergoing active 
treatment. The purpose of this paper is to review the state of knowledge regarding 
CRF in patients with advanced cancer. In this paper, we review the evidence 
pertaining to the aetiologic factors associated with fatigue, the impact of fatigue on 
the patient with advanced cancer and current trends in its management.  
 
Aetiologic factors associated with fatigue in patients with advanced cancer 
The aetiology of CRF is complex and remains unclear in patients with advanced 
cancer (9). The literature indicates that aetiologic factors associated with CRF could 
comprise (but are not limited to) cachexia, infection, anaemia, neurological changes, 
psychological distress, metabolic and endocrine disorders, over-exertion, 
medications, side-effects of antineoplastic treatment and paraneoplastic neurological 
syndromes (10). In recent years, the role of a number of biological response 
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modifiers (e.g. interferon, tumour necrosis factor, IL-1 and IL-6) (11, 12), and the 
patient’s genetic makeup (13) in CRF have also been explored. Although these 
studies have focused on people experiencing cancer treatment-related fatigue, there 
is preliminary evidence to indicate  relationships between genetic makeup, cytokine 
markers and symptoms in oncology patients and their family caregivers (13). One 
recent study, for example, reported an association between a functional promoter 
polymorphism in the TNF-α gene with the severity of both sleep disturbance and 
morning fatigue (13).  
 
The evidence further indicates that the aetiologic factors associated with CRF could 
vary between those in the earlier stages of the cancer trajectory compared to those 
who are at the more advanced stage. For example, although it is repeatedly reported 
that anaemia is associated with fatigue in patients undergoing treatment, it is also 
reported that there is no association between haemoglobin levels and fatigue in 
patients with advanced cancer (14, 15). For another example, although fatigue is 
thought to be a common side effect of antineoplastic treatment in cancer patients, 
antineoplastic treatments received by patients with advanced cancer normally aim to 
improve symptom control and quality of life, and can in some cases alleviate their 
fatigue and other symptoms (16, 17).   
 
One UK observational study of 122 patients with advanced cancer provided further 
empirical evidence of potential differences in contributors to CRF (15). The study 
reported no relationships between the level of fatigue and age, sex, diagnosis, 
presence or sites of metastases, anaemia, dose of opioid or steroid, or a range of 
haematological markers or biochemical indices (except urea), but did identify 
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significant associations between fatigue, pain and dyspnoea scores (15). Recent 
studies which have investigated the inter-relationship between and co-existence of 
fatigue and other symptoms (18, 19), similarly emphasise the greater significance of 
symptom burden as a contributor to fatigue in patients with advanced cancer.  
  
The impact of fatigue for patients with advanced cancer 
Fatigue is associated with impaired health-related quality of life in patients with 
cancer at all stages of cancer, but particularly for those whose disease is more 
advanced (20-23). For example, a study of 40 patients with advanced cancer 
admitted to an academic palliative care unit reported a high correlation between 
fatigue within 24 hours of admission and  individual quality of life scores at 7 days 
(23). Moreover, the experience and impact of fatigue in patients with advanced 
cancer is likely to have some unique characteristics that have implications for 
management strategies. One qualitative study of patients with advanced cancer 
described how fatigue affects the physical, psychological, social and spiritual aspects 
of their lives (24). These individuals often find that they are unable to do much and 
they particularly struggle to manage fatigue (8, 25, 26). The perception of “nothing 
can be done” for their fatigue is often shared among families and health 
professionals (25). As a result, the effect of fatigue on patients can be tremendous, 
which they express in terms of the burden they impose on others, their inability to 
participate in family and other social activities, and cognitive impairments such as 
memory loss and loss of ability to concentrate (8, 24-27). Moreover, patients with 
advanced cancer are more likely to associate fatigue with the process of adjusting to 
living with a terminal illness and ultimately death (24, 27). Individuals with advanced 
disease may thus perceive fatigue in different ways to those individuals who 
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experience fatigue primarily associated with curative treatment for their disease (28, 
29).  
 
In 1996, Sutchilffe-Chidegey and Holme’s cross-sectional survey offered insights into 
perceived distress levels associated with fatigue in patients with advanced cancer, 
where 49% (n=100) of participants perceived fatigue as a distressing symptom (4). 
This study also reported that the level of perceived distress varied among patients, 
professionals and bereaved carers, with only nine per cent of professional carers 
(n=60) and 17% of bereaved carers (n=30) perceiving fatigue as a distressing 
symptom (4). Such findings suggest that people other than the patient may have 
limited insight into such a subjective experience.  
 
For some patients with advanced cancer, fatigue could also be perceived as 
“necessary” or unavoidable in the terminal phase of life (30). Some have suggested 
that treatment of fatigue is no longer indicated at end-of-life as fatigue may provide 
protection and shielding from suffering (30). While there is some agreement that 
fatigue negatively influences quality of life among patients with advanced cancer, the 
association between fatigue and quality of life and negative emotions could change 
during the last days and weeks of life (31). However, while attitudes towards fatigue 
might change over time, it is still a burdensome symptom even during the last week 
of life (32) and therefore worthy of further investigation.  
 
Other studies involving patients with advanced cancer report that the decline in 
performance status that is associated with advanced cancer is associated with 
increased fatigue levels. For example, one study reported that as performance status 
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declined,  fatigue interfered with subjects’ physical activities such as walking (36.3%, 
n=157), normal work (31.8%), mood (21.7%) and enjoyment of life (19.1%) (33). 
Other studies report that fatigue is highly and negatively correlated with performance 
status (34-38). One Japanese longitudinal study offered some insights into the 
specific physical and psychological factors correlating with fatigue in terminally ill 
patients with cancer over three time points (33). At time 1 (the second visit to the 
palliative outpatient department), greater fatigue was significantly correlated with 
psychological distress, lower performance status, dyspnoea and appetite loss. At 
time 2 (a week after time 1), greater fatigue was significantly correlated with higher 
psychological distress, and lower performance status at time 1. Fatigue was also 
positively correlated with deterioration in psychological distress, performance status, 
and dyspnoea severity during the period between time 1 and 3. Another study that 
attempted to differentiate factors that affected fatigue and physical function in lung 
cancer patients did so cross-sectionally (39). Using multiple regression analysis, the 
researcher identified that performance status scores, weakness and depression 
scores were correlated independently with fatigue.  Hence, while studies report that 
CRF is almost universally a distressing and disruptive symptom, the experience and 
impact of fatigue for people with advanced cancer as compared to early stage 
cancer has some unique dimensions. These unique features are associated with the 
particular meanings and declining performance characteristic of progressive and life-
limiting disease. 
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Figure 1. The impact of cancer-related fatigue on patients with advanced cancer and others. 
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The management of cancer-related-fatigue in people with advanced cancer 
The management of CRF in patients with advanced cancer is complex and may 
involve a range of treatment measures associated with pharmacologic and non-
pharmacologic strategies (9). These measures aim to target potentially reversible 
aetiologic factors that are known to contribute to CRF (9).. 
 
  
Pharmacological management 
A range of pharmacologic agents is used for the treatment CRF. These agents 
include psychostimulants (e.g. methylphenidate), paroxetine and progestational 
steroids (e.g. megestrol acetate). The effectiveness of each class of medication and 
related concerns are discussed below.  
 
Psychostimulants 
Research on symptomatic treatment of fatigue in patients with advanced cancer has 
concentrated on stimulant drugs such as methylphenidate and donezepil. 
Methylphenidate is reported as effective in several uncontrolled trials or retrospective 
studies that investigated fatigue in patients with advanced cancer (40-42). In 2005, 
one randomised placebo-controlled trial of 152 patients with breast cancer reported 
favourable results for methylphenidate, which was significantly more effective than 
placebo in improving fatigue after chemotherapy. However, this study did not report 
on the staging of the disease of this sample of women with breast cancer. In 2006, 
another randomised placebo-controlled trial of 112 patients with advanced cancer 
receiving palliative care reported no difference between placebo and 
methylphenidate (43). In light of these equivocal findings, a systematic review 
concluded that the two methylphenidate trials for CRF did not provide sufficient 
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evidence to recommend its use in practice; however  a later  meta-analysis favoured 
the use of a dose of 10 to 20 mg per day titrated to response (44). This review 
concluded that serious adverse effects were minimal but contra-indications should 
be reviewed before prescribing  (44). In 2010, a retrospective analysis reported that 
the side effects of methylphenidate (10-20mg/d) are well tolerated in patients with 
advanced cancer (45). According to the information retrieved from the international 
trial registries, more trials are now underway to determine its effects in patients with 
advanced cancer.  
 
With respect to donezepil, the effects are still not certain in patients with advanced 
cancer. Although donezepil was reported as effective in the treatment of opioid-
induced sedation in an uncontrolled trial (46), one recent randomised placebo-
controlled trial of 142 patients with advanced cancer also reported that it was not 
superior to placebo (47). Another recent randomised, double-blinded, placebo-
controlled trial conducted with 39 patients with advanced cancer reported potential 
benefits of using dexamphetamine (48). Specifically, the use of 10mg twice daily for 
eight days was well tolerated with minimal side effects and improved fatigue levels 
on day two, but not at the end of the study. These results suggest uncertainty about 
the effectiveness of dexamphetamine beyond day two. With the consideration that 
the current tested dosing was well tolerated, further investigations with higher dosing 
may be warranted. 
 
Paroxetine, progestational steroids and Acetyl-L-Carnitine 
In 2010, two meta-analysis were conducted in a Cochrane systematic review (49). 
The meta-analysis of two studies (n=625) was conducted for paroxetine and 
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indicated no difference between paroxetine and placebo for the treatment of CRF in 
patients with advanced cancer (49). Similarly, the meta-analysis of four studies 
(n=587) investigating the effect of progestational steroids on CRF also reported that 
it was not superior to placebo (49). Acetyl-L-Carnitine was compared against 
placebo in a double-blind randomised-controlled trial (RCT) with patients with 
advanced cancer and was not superior to placebo (50). 
 
Non-pharmacological management  
A range of non-pharmacological management strategies are used in the 
management of CRF (51). This section discusses the evidence base for each of the 
non-pharmacologic management strategies as recommended by the National 
Comprehensive Cancer Network (NCCN), and their potential application for patients 
with advanced cancer (52). Due to the lack of direct evidence for patients with 
advanced cancer, some of the recommended strategies in the NCCN guidelines are 
based primarily on evidence for patients with early stage cancer (52), and their 
application to patients with advanced cancer is yet to be tested in randomised trials. 
The key strategies reviewed in this section include exercise, sleep and rest, energy 
conservation, complementary therapies and psychosocial interventions. 
 
Exercise 
A Cochrane review by Cramps and Daniel (2008) of 28 RCTs that studied patients 
with cancer of all stages concluded that moderate exercise appears to have benefit 
in the management of CRF both during and after active cancer treatment (53), 
particularly in patients with breast cancer and prostate cancer. However, there is not 
sufficient evidence to determine the best type or intensity of exercise for reducing 
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CRF (53). Further, this review only identified few studies that included samples with 
patients who had advanced cancer (53). 
 
The few available studies suggest that at least some groups of patients with 
advanced cancer may also benefit from exercise based interventions. One 
Norwegian study of 63 patients with advanced cancer receiving palliative care pilot-
tested an exercise program and reported that the exercise participants had 
significantly less physical fatigue and increased walking distance (54). This program 
consisted of two 50-minute sessions twice a week for 6 weeks. A combination of 
strength building, standing balance, and aerobic exercise was used in this program. 
Another small pilot study was conducted by Porock and her research team to 
evaluate an exercise program for nine patients with advanced cancer who were 
enrolled in a home hospice program (55). In this intervention, a physical therapist 
guided participants to perform a range of strategies throughout the day (e.g. walking, 
performing arm exercises with resistance, marching in place, and dancing). All 
participants were able to increase their activity level over a 2-week period without 
increased fatigue. There was also a trend toward increased quality of life and 
decreased anxiety. In 2003, a 12-week exercise program was tested in 82 men with 
locally advanced/ metastatic prostate cancer receiving androgen deprivation therapy, 
as compared to a wait-list control group (56). Patients who were in the exercise 
group reported less interference of fatigue with daily activities (p=0.002) and better 
quality of life (p=0.001). In addition, they also demonstrated high levels of upper 
body (p=0.009), and lower body (p<0.001) muscular fitness than men in the control 
group. 
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Although there is some preliminary evidence now suggesting the benefits of exercise 
in patients with advanced cancer, the evidence is not yet conclusive due to the lack 
of RCTs. Two recent RCTs of patients with advanced cancer (57, 58) reported 
contradictory results with regards to the benefits of exercise for patients with 
advanced cancer. One possible explanation may be that the more effective 
intervention evaluated by Headley et al (2004) required patients to participate in a 
less intense program (a 30-minute seated exercise program, three times a week, 
with one a week break between sessions) (57), as compared to the less effective 
intervention of Brown et al (2006) that asked patients to perform stretching, strength, 
balance and gait training over eight 90 minute sessions in four weeks (58).  Although 
it is suggested that a 30 minute seated exercise regimen is a feasible management 
strategy for patients with advanced cancer, further RCTs are needed to duplicate 
these results in the various populations of patients with advanced cancer. While 
health professionals need to be informed by high quality trials that can support 
specific effective exercise regimen for this patient group, research efforts should also 
be directed to understanding what patient responses are to these recommendations 
for exercise therapy, what are their confidence level with regards to carrying out the 
exercises, and the factors that may influence the use of exercise.   
 
Sleep and rest 
In general, patients with cancer can experience disruptions in both the quantity and 
the quality of their sleep (59, 60).  Due to the close relationship between sleep 
disturbance and fatigue (61), health care professionals commonly recommend 
strategies for improving sleep quality to patients with cancer-related fatigue (62), and 
they may be the most frequent self-management activities patients perform (51, 63, 
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64).  Although there is compelling evidence suggesting the effectiveness of sleep 
hygiene programs in insomnia (65-68), there are limited trials testing non-
pharmacological strategies in managing sleep disturbance in patients with advanced 
cancer. In one RCT, forty-six patients with advanced cancer receiving hospice care 
were allocated to three groups: massage group, aromatherapy group and control 
group in the hospice setting in the UK (69). The results of this study demonstrated 
significant clinical improvements in sleep disturbance and depression scores. 
However, the sample was too small to detect statistically significant differences in 
sleep disturbance.  
 
There is also now some preliminary evidence that shows the potential benefits of an 
8 week Carlson’s Mindfulness-based Stress Reduction program in patients with early 
stage cancer (70). The components of the program included body scan meditation, 
sitting, walking, meditation and hatha yoga. The number of participants with total 
sleep scores over eight (≥ 5 indicates sleep disturbance with the use of PSQI) was 
reduced from 70% at baseline to 49% post-intervention. Other than the structured 
programs mentioned above, the literature has documented a list of strategies 
undertaken by palliative/ cancer care professionals. These range from avoiding 
stimulating substances (such as caffeine, nicotine) before bedtime to light exercise 
during the day time (60, 71). These interventions have not yet been formally tested in 
this population, despite a prevalence of sleep alterations in patients with advanced 
cancer of approximately 71 per cent (72-74). A recent UK study using 
comprehensive patient reports and objective measures such as actigraphy reported 
the manifestations for patients with advanced cancer are high levels of sleep 
fragmentation and movement during sleep, rather than the length of sleep (75). It is 
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important that appropriate sleep therapies are formally evaluated in patients with 
advanced cancer. 
 
Energy conservation 
Energy conservation is defined as “the deliberate, planned management of an 
individual’s personal energy resources to prevent their depletion” (76). The goal of 
energy conservation is to balance rest and activity during times of high fatigue so 
that valued activities and goals can be maintained. Energy conservation involves a 
number of strategies: taking additional rest periods, priority setting, delegation, 
pacing oneself, and planning high-energy activities at times of peak energy. A 
multisite RCT of 396 patients with various cancer at different stages undergoing 
chemotherapy and radiotherapy reported that the intervention group using these 
strategies experienced a greater decrease in fatigue over time compared with the 
control group (p<0.01) (76). A further recent study reported the experiences and 
outcomes of a fatigue clinic in a comprehensive cancer centre (62). This study 
reported that energy conservation was recommended to 98.5% of patients with CRF 
(n=260), regardless of cancer stage. However, the authors also reported that they 
faced challenges in encouraging patients to delegate tasks to family or hire help. 
While some patients were reluctant to seek help, families were enthusiastic about 
participating in treatment plan recommendations (62). The NCCN guideline for 
Cancer Related Fatigue recommends energy conservation as a “general strategy for 
management of fatigue” for patients with advanced cancer and their caregivers. 
However, there is a lack of research suggesting its effectiveness in patients with 
advanced cancer who are not undergoing treatment.  
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Complementary therapies 
Complementary therapies such as massage therapy (77, 78), yoga (79), breathing 
exercises (80, 81), muscle relaxation (82, 83) and mindfulness-based stress 
reduction (70, 84-86) have been evaluated in pilot studies. The preliminary data 
suggest that these therapies may have an effect in reducing fatigue in patients with 
cancer. These strategies have also been recommended for the management of CRF 
in a number of clinical guidelines for the management of CRF (9, 30, 87). However, 
these interventions were either supported by indirect evidence (88, 89) or a case 
report (90), or tested with benefits in patients who were not in their advanced stage 
of disease (82).  
 
Psychosocial interventions 
The NCCN guideline for CRF management recommends that patients should be 
counselled about coping and educated on how to deal with anxiety and depression, 
which are commonly known to be associated with fatigue during cancer treatment 
(52). A recent  Cochrane systematic review in 2009, involving 27 studies of a total of 
3324 participants, reported limited evidence that psychosocial interventions are 
effective in reducing fatigue during active treatment in patients with cancer (91). Of 
these studies, only five studies were designed with the focus of fatigue, with four 
being effective (p<0.05). The five interventions were brief, consisting of three 
individual sessions provided by oncology nurses. The general content of these 
interventions included education about fatigue, self-care or coping techniques, and 
learned activity management.  Only three of these studies reported sustained effects 
at follow-up. To date, there is scant evidence suggesting the effectiveness of 
psychosocial interventions in patients with advanced cancer (92).  
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Summary 
Despite the fact that many advances have been made in understanding and 
managing fatigue in patients with cancer, these advances have primarily been made 
for patients with cancer undergoing primary or adjuvant treatment. Prevalence data 
for CRF suggests that this symptom is not well managed in patients with advanced 
disease. While the evidence base relating to management of cancer treatment-
related fatigue is a useful starting point for identifying strategies for managing fatigue 
associated with advanced cancer, differing aetiologies and experiences means that 
management strategies may need to be tailored for this population.  
 
Researchers have tested a number of interventions, both pharmacological and non-
pharmacological, with the aim of reducing the severity and impact of CRF. While 
there have been many efforts to test pharmacological agents in patients with 
advanced cancer in the management of CRF, a number of non-pharmacological 
management strategies are recommended for patients with advanced cancer, in 
spite of the fact that they are not well tested in patients with advanced cancer (see 
table 1). Most of these interventions require patients to respond with a number of 
health behaviours (e.g. taking medications, exercising, delegating tasks). These 
responses may have a direct impact on the efficacy of some of these interventions in 
relieving CRF. For patients with advanced cancer, further research is required to 
investigate the effectiveness of these interventions with good quality controlled trials 
and investigate how patients respond to evidence based recommendations.  
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Recommendations for nursing practice 
• It is important for nurses to encourage patients with advanced cancer or their 
caregivers to openly discuss their fears, concerns and experience of CRF. 
• The literature shows that patients often are not aware of treatment options. 
Nurses can support the self-management of patients by providing evidence-
based information in relation to fatigue management. 
o Preliminary research indicates some benefits of exercise in the 
management of fatigue in patients with advanced cancer. Although 
more research is warranted to determine the most effective intensity 
and mode of exercise, low intensity seated exercise appears to be 
appropriate for this population.  
o Evidence pertaining to patients with early stage cancer indicates the 
potential benefits in a number of management strategies such as 
energy conservation and sleep hygiene behaviours. These strategies 
can be recommended for use in patients with advanced cancer as 
appropriate. 
o Although more trials are currently underway, the use of 
methylphenidate could be discussed with medical staff for 
consideration in managing CRF in some patients with advanced cancer. 
 
 
 
 
 
18 
 
Table 1. Current evidence for the management of CRF in patients with advanced cancer 
Interventions Benefits for reducing CRF in 
patients with advanced 
cancer 
NHMRC Level of 
evidence 
The directness of 
evidence for patients 
with advanced cancer  
Remarks 
Pharmacological     
Methylphenidate Potential benefits Level I Direct evidence A meta-analysis favoured the use of a dose of 
10 to 20 mg per day titrated to response (44) 
Donezepil Not superior to placebo Level II Direct evidence  
Dexamphetamine Potential benefits Level II Direct evidence The results of a RCT suggest uncertainty 
about the effectiveness of dexamphetamine 
beyond day two (48)  
Paroxetine Not superior to placebo Level I Direct evidence  
Progestational steroids Not superior to placebo Level I Direct evidence  
Acetyl-L-Carnitine Not superior to placebo Level II Direct evidence  
     
Non-pharmacological     
Exercise Potential benefits Level II Direct evidence The most appropriate intensity of exercise yet 
to be determined patients with advanced 
cancer (57, 58) 
Sleep/rest Potential benefits Level II Indirect evidence  
Energy conservation Potential benefits Level II Indirect evidence  
Complementary therapies 
 
Potential benefits Level III or level IV Indirect evidence  
Psychosocial interventions Potential benefits Level I Indirect evidence  
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